Menu Back toParallel Scientific Advice: Increasing International Dialogue Early in the Product Lifecycle
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
DIA 2021 Global Annual Meeting
Parallel Scientific Advice: Increasing International Dialogue Early in the Product Lifecycle
Shannon Thor, PharmD, MS
- International Policy Analyst, Office of Global Policy & Strategy, Europe Office
- FDA, United States
The Parallel Scientific Advice (PSA) procedure is a process for EMA and FDA to concurrently exchange with sponsors their views on scientific issues during the development phase of new medicinal products (i.e., new human drugs and biologics). Such interactions are expected to increase dialogue between the two agencies and sponsors from the beginning of the lifecycle of a new product, provide a deeper understanding of the bases of regulatory decisions, optimize product development, and avoid unnecessary testing replication or unnecessary diverse testing methodologies. This session will be led by EMA and FDA PSA participants and program managers, as well as a participant offering the industry perspective. Attendees will better understand the PSA procedure, how to apply, and expectations on outcomes.
Learning Objective : Explain the Parallel Scientific Advice (PSA) procedure framework and timelines; Identify best candidates for PSA and best practices for request letters; review statistics on utilization of the PSA procedure; Describe Industry’s and each Agency’s unique perspective and contribution to PSA.
PSA: FDA Division Perspective
Kelly Richards, MSN, RN, RAC
- Senior Regulatory Health Project Manager, Gastroenterology , ORO, OND, CDER
- FDA, United States
PSA: EMA Perspective
Thorsten Vetter, DrMed
- Senior Scientific Officer, Scientific Advice
- European Medicines Agency, Netherlands
PSA: A Sponsor Perspective
Petra Pavlickova, PhD, RAC
- Associate Director, Regulatory Affairs
- Bristol-Myers Squibb Company, United States